BIG BUSINESS
Biological drugs (biologics) -pharmaceutical drugs that are based on biological molecules such as proteins -accounted for almost one-quarter of drug spending worldwide in 2015. That fraction is set to continue to grow in the years ahead.
Most biologics that achieve huge sales are targeted at common medical conditions. Drugs that tackle various types of cancer, diabetes and speci c immune disorders represented more than half of global spending on biologics in 2015.
Remicade (in iximab; immune disorders)
Several biosimilars went on sale in the EU in 2015 and in the United States in 2016.
SALES IMPACT
Many biologics that would otherwise experience a steady or growing demand show a sharp loss of sales on the launch of their biosimilars.
Avastin (bevacizumab; cancer)
Biosimilar Mvasi has been approved for EU and US markets, but has reached neither. 
BLOCKBUSTE S ON THE B INK
Time is running out for the manufacturers of some of the most lucrative biologics, with patents expiring in crucial markets over the next ve years. Biosimilar developers are prepared, with pre-approved drugs ready to launch when these markets open. Notably, some biologics are covered by further patents related to their manufacture; these continue to o er protection after the original drug patent has expired. 
ON T ACK FO APP OVAL
Biosimilars are more costly and di cult to produce than generic versions of small-molecule drugs. It can take 5-10 years and an investment of US$100 million-250 million to bring a biosimilar to market, compared with about 2 years and $1 million-10 million to develop a conventional generic -particularly in the complex patent landscape of the United States.
Biologic

Biosimilar
STA T EVE SE ENGINEE ING
The original biologic is analysed with methods such as mass spectrometry to reveal its amino-acid sequence, protein structure and any chemical modi cations. These pro les will be compared with those of prospective biosimilars.
CELL-CULTU E CONDITIONS
Even when following the same genetic instructions, di erent cell lines can produce variants of a particular protein. Biosimilar developers must therefore identify an appropriate cellular factory, as well as optimize those cells' growth conditions, to ensure that their product closely resembles the original biologic.
TESTING THE FUNCTION
Various assays are used to test how well a prospective biosimilar binds to its biological target, and to con rm that the drug replicates the e ect and speci city of the original biologic.
FINDING THE FO MULATION
If a biologic is not properly prepared or mixed, it can misfold, degrade or aggregate. Consequently, biosimilar developers must identify manufacturing methods that result in a stable, reliable product.
EGULATO Y EVIEW
On the basis of the clinical data, a regulatory authority decides whether the a biosimilar is su ciently similar to the original biologic. Further testing in people might be required.
CLINICAL CONFI MATION
Testing a biosimilar in people is faster than evaluating a biologic. Typically, only a phase I trial to show that the drug is safe and a phase III trial to show that it has an e cacy similar to that of the original are needed. 
Humira (adalimumab)
Immune disorders
Herceptin* Cancer
Avastin † Cancer
Eylea (a ibercept) Vision
Stelara (ustekinumab) Immune disorders
Lucentis ( 
